Several strains of Lactobacillus probiotics show genuine promise for treating and preventing bacterial vaginosis, though they work best when paired with standard antibiotic treatment rather than used alone. The most studied strains include L. rhamnosus GR-1, L. reuteri RC-14, and L. crispatus CTV-05, all of which have clinical trial data behind them. That said, the CDC does not yet endorse probiotics as a standalone or add-on therapy for BV, so the evidence is encouraging but not settled.
Why Lactobacillus Matters for BV
A healthy vaginal environment is dominated by Lactobacillus bacteria, which produce lactic acid and natural antimicrobial compounds that keep the pH between about 4.5 and 6.0. That acidic environment makes it difficult for BV-associated bacteria to thrive. When Lactobacillus populations drop and other bacteria take over, the pH rises, and BV develops. The logic behind probiotic treatment is straightforward: reintroduce Lactobacillus to restore that protective acid balance.
Strains With the Strongest Evidence
Not all probiotics are interchangeable. The strain matters, and only a handful have been tested specifically for BV in clinical trials.
L. rhamnosus GR-1 and L. reuteri RC-14
This combination is one of the most studied pairings for vaginal health. In a trial of 50 women with BV, participants took antibiotics first and then received oral tablets containing both strains for 15 days. By the end of the study, 92% had complete Lactobacillus recolonization of the vagina. These two strains are commonly found in supplements marketed for vaginal health and are typically dosed at around 2.5 billion CFU each, taken daily for 12 weeks in longer prevention protocols.
L. crispatus CTV-05 (LACTIN-V)
L. crispatus is the species most commonly found in healthy vaginal microbiomes, which makes it a natural candidate for BV treatment. LACTIN-V, a vaginal insert containing a specific L. crispatus strain, was tested in women who had just completed antibiotic treatment. Among those whose antibiotics successfully cleared BV, only 25% experienced a recurrence within 12 weeks on LACTIN-V, compared to 43% on placebo. At 24 weeks, recurrence was 34% versus 52%. Colonization rates were high: nearly 84% of women in the antibiotic-success group still had detectable L. crispatus at 12 weeks.
L. rhamnosus TOM 22.8
A systematic review of probiotic regimens identified this strain as particularly effective. At a dose of 10 billion CFU per day taken orally for 10 days, it improved Nugent scores (a lab measure of vaginal bacterial balance) in 96.7% of participants, with improvements holding at 30 days. Other strains showing therapeutic potential include L. plantarum, L. acidophilus, and additional L. crispatus strains, generally at doses ranging from 100 million to about 5 billion CFU per day.
How Much Probiotics Reduce Recurrence
BV is notoriously recurrent. Up to half of women who take antibiotics alone will have BV return within months. This is where probiotics may offer the most practical value. A meta-analysis of randomized controlled trials found that probiotics reduced the risk of BV recurrence by 45% compared to placebo or antibiotics alone (recurrence rates of about 15% versus 26%). A separate systematic review of 18 studies involving over 1,600 women confirmed that combining antibiotics with probiotics significantly reduced recurrence at both one and three months.
The key takeaway is that probiotics appear more useful for preventing BV from coming back than for curing an active infection on their own. Starting probiotics after completing antibiotic treatment is the approach supported by the most data.
Oral vs. Vaginal Probiotics
Probiotics for BV come in two forms: oral capsules and vaginal suppositories or inserts. A double-blind clinical trial compared the two head-to-head. Both groups saw their Nugent scores drop from the 8 to 9 range (indicating BV) down to about 3 (indicating a healthy balance) over four weeks. The difference between the two methods was not statistically significant, meaning oral and vaginal delivery were equally effective in that trial.
Oral probiotics are more convenient and widely available. Vaginal formulations deliver bacteria directly to the site, which may help with colonization speed. If you have a preference for one over the other, the current evidence suggests either route can work.
Dosage and Duration
Clinical trials have used a wide range of doses, from 10 million to 30 billion CFU per day, with treatment durations spanning from 6 days to 4 months. There is no universally agreed-upon “best” regimen, but some patterns emerge from the research.
For active BV treatment (after antibiotics), most successful trials used at least 1 billion CFU per day for a minimum of one to four weeks. For recurrence prevention, longer courses tend to perform better. Trials lasting 12 weeks to 4 months showed more sustained improvements in vaginal bacterial balance. One protocol that showed strong results used 5.4 billion CFU per capsule twice daily for the first week, then once daily for a total of 120 days.
If you’re choosing a supplement, look for one that lists specific strain names (not just “Lactobacillus blend”), contains at least 1 billion CFU, and ideally includes one of the well-studied strains mentioned above.
What the Guidelines Actually Say
Despite the promising trial results, the CDC’s current STI treatment guidelines state that no studies support probiotics as an adjunctive or replacement therapy for BV. This doesn’t mean probiotics are useless. It reflects the fact that trial designs, strains, and dosing have varied so much that the evidence hasn’t coalesced into the kind of consistent, large-scale proof that guideline committees require. Standard treatment for BV remains antibiotic therapy.
Many gynecologists are open to patients trying probiotics alongside antibiotics, particularly for women dealing with frequent recurrences. The safety profile is reassuring for most people: the most common side effects are mild digestive symptoms like gas, bloating, and occasional constipation. People with weakened immune systems should avoid live-bacteria products, and probiotics should not be given to premature infants. If you’re lactose intolerant, check labels, as some formulations contain lactose.
Practical Approach to Trying Probiotics for BV
If you’re dealing with recurrent BV and want to try probiotics, the approach best supported by research is to complete your prescribed antibiotic course first, then begin a probiotic containing L. rhamnosus GR-1 and L. reuteri RC-14, L. crispatus, or L. rhamnosus TOM 22.8. Choose a product with at least 1 billion CFU per dose, and plan to continue for at least four weeks, ideally longer if you’re focused on preventing recurrence. Oral and vaginal forms both work, so pick whichever fits your routine.
Probiotics are not a guaranteed fix, and they don’t replace antibiotics for an active BV infection. But for the roughly half of women who see BV return after standard treatment, adding the right probiotic strains is one of the more evidence-backed strategies available for breaking that cycle.